Halozyme Therapeutics Inc. [NASDAQ: HALO] loss -7.20% on the last trading session, reaching $39.51 price per share at the time. The company report on November 23, 2020 that Halozyme Raises Full Year 2020 Guidance.
– Raises 2020 Guidance to $265 Million to $275 Million in Revenues, Up from $250 Million to $260 Million, and EPS of $0.90 to $0.95, Up from $0.80 to $0.85 -.
Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced that it is updating 2020 financial guidance to reflect the signing of a global collaboration and license agreement with Horizon Therapeutics plc.
Halozyme Therapeutics Inc. represents 136.58 million in outstanding shares, while the company has a total market value of $5.22 billion with the latest information. HALO stock price has been found in the range of $39.35 to $44.53.
If compared to the average trading volume of 1.91M shares, HALO reached a trading volume of 2297161 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Halozyme Therapeutics Inc. [HALO]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for HALO shares is $39.36 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on HALO stock is a recommendation set at 2.30. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
JP Morgan have made an estimate for Halozyme Therapeutics Inc. shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on September 14, 2020. While these analysts kept the previous recommendation, The Benchmark Company raised their target price to Buy. The new note on the price target was released on July 01, 2020, representing the official price target for Halozyme Therapeutics Inc. stock. Previously, the target price had yet another raise from $18 to $27, while Piper Sandler kept a Overweight rating on HALO stock. On January 09, 2020, analysts increased their price target for HALO shares from 17 to 24.
The Average True Range (ATR) for Halozyme Therapeutics Inc. is set at 2.13, with the Price to Sales ratio for HALO stock in the period of the last 12 months amounting to 26.16. The Price to Book ratio for the last quarter was 54.87, with the Price to Cash per share for the same quarter was set at 2.62.
Trading performance analysis for HALO stock
Halozyme Therapeutics Inc. [HALO] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -2.83. With this latest performance, HALO shares gained by 5.73% in over the last four-week period, additionally plugging by 71.63% over the last 6 months – not to mention a rise of 105.67% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for HALO stock in for the last two-week period is set at 55.35, with the RSI for the last a single of trading hit 50.35, and the three-weeks RSI is set at 58.04 for Halozyme Therapeutics Inc. [HALO]. The present Moving Average for the last 50 days of trading for this stock 33.85, while it was recorded at 40.38 for the last single week of trading, and 26.48 for the last 200 days.
Halozyme Therapeutics Inc. [HALO]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and Halozyme Therapeutics Inc. [HALO] shares currently have an operating margin of -18.70 and a Gross Margin at +76.76. Halozyme Therapeutics Inc.’s Net Margin is presently recorded at -36.86.
Return on Total Capital for HALO is now -8.43, given the latest momentum, and Return on Invested Capital for the company is -19.05. Return on Equity for this stock declined to -42.41, with Return on Assets sitting at -14.36. When it comes to the capital structure of this company, Halozyme Therapeutics Inc. [HALO] has a Total Debt to Total Equity ratio set at 438.72. Additionally, HALO Total Debt to Total Capital is recorded at 81.44, with Total Debt to Total Assets ending up at 71.14. Long-Term Debt to Equity for the company is recorded at 417.42, with the Long-Term Debt to Total Capital now at 77.48.
Reflecting on the efficiency of the workforce at the company, Halozyme Therapeutics Inc. [HALO] managed to generate an average of -$547,273 per employee. Receivables Turnover for the company is 4.38 with a Total Asset Turnover recorded at a value of 0.39.Halozyme Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 16.40 and a Current Ratio set at 18.50.
Halozyme Therapeutics Inc. [HALO]: An earnings per share (EPS) analysis
With the latest financial reports released by the company, Halozyme Therapeutics Inc. posted -0.24/share EPS, while the average EPS was predicted by analysts to be reported at -0.15/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -60.00%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for HALO. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Halozyme Therapeutics Inc. go to 58.00%.
An analysis of insider ownership at Halozyme Therapeutics Inc. [HALO]
There are presently around $5,357 million, in the hands of institutional investors. The top three institutional holders of HALO stocks are: ARTISAN PARTNERS LIMITED PARTNERSHIP with ownership of 15,517,924, which is approximately -7.672% of the company’s market cap and around 0.90% of the total institutional ownership; BLACKROCK INC., holding 13,209,235 shares of the stock with an approximate value of $521.9 million in HALO stocks shares; and VANGUARD GROUP INC, currently with $502.86 million in HALO stock with ownership of nearly -2.454% of the company’s market capitalization.
Positions in Halozyme Therapeutics Inc. stocks held by institutional investors increased at the end of November and at the time of the November reporting period, where 126 institutional holders increased their position in Halozyme Therapeutics Inc. [NASDAQ:HALO] by around 9,970,451 shares. Additionally, 129 investors decreased positions by around 11,386,756 shares, while 45 investors held positions by with 114,225,337 shares. The mentioned changes placed institutional holdings at 135,582,544 shares, according to the latest SEC report filing. HALO stock had 35 new institutional investments in for a total of 1,769,925 shares, while 27 institutional investors sold positions of 1,407,336 shares during the same period.